reports
ONWARD® Medical Announces Participation in Stifel European Healthcare ...
ONWARD® Medical Announces Participation in Stifel European Healthcare Summit CEO Dave Marver will meet with investors to discuss the Company’s achievements and upcoming milestones EINDHOVEN, the Netherlands, June 26, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its participation in the Stifel European Healthcare Summit in Lyon, France from June 25-27th. CEO Dave Marver will mee...
ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe C...
ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation EINDHOVEN, the Netherlands, June 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that the Company will be highlighted in a main stage keynote at HLTH Europe, a premier event for digit...
ONWARD® Medical Announces Results of Annual General Meeting of Shareho...
ONWARD® Medical Announces Results of Annual General Meeting of Shareholders THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, the Netherlands, June 13, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces all proposed resolutions at its...
- Jacob Mekhael
- Thomas Vranken
- Thomas Vranken
Onward Medical Takeaways from Up-LIFT panel discussion
Yesterday, Onward held a webcast to discuss its Q1 results and hosted a panel to discuss the recently published Up-LIFT trial data in Nature (Moritz et al., 2024). Beyond our note highlighting the results of the study, we have compiled our key takeaways from the discussion.
ONWARD® Medical berichtet über das 1. Quartal 2024 und die bisherigen ...
ONWARD® Medical berichtet über das 1. Quartal 2024 und die bisherigen Höhepunkte des Jahres Ergebnisse der Up-LIFT-Zulassungsstudie in Nature Medicine veröffentlicht Einreichung des De-Novo-Antrags für das ARC-EX®-System bei der FDA Erfolgreiche Einwerbung von 20 Mio. EUR an Eigenkapital EINDHOVEN, Niederlande, May 24, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), das Medizintechnologieunternehmen, das innovative Rückenmarkstimulationstherapien zur Wiederherstellung von Bewegung, Funktion und Unabhängigkeit für Menschen mit Rückenmarksverletzungen (Spinal Cord Injury,...
ONWARD® Medical fait le point sur le premier trimestre 2024 et sur les...
ONWARD® Medical fait le point sur le premier trimestre 2024 et sur les faits marquants de l’année écoulée La revue Nature Medicine a publié les résultats de l’essai clinique pivot Up-LIFT Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX® System basée sur les risques (demande « De Novo ») Levée de fonds de 20 millions d’euros EINDHOVEN, Pays-Bas, 24 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), une société de technologie médicale qui crée des thérapies innovantes de stimulation de la moelle épinière pour que les personnes souffrant ...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Lewi
- Thomas Couvreur
Onward Medical FIRST LOOK: 1Q24 update underpinned by strong Up-LIFT d...
Onward announced its 1Q24 update, and confirmed its FY24 outlook and key milestones. 2024 is set to become the year of its first launch, with ARCEX approval expected toward YE24. Meanwhile, the pivotal trial in blood pressure control with ARCIM is slated to kick off with first patient in late 2024/early 2025. 1Q24 cash landed at € 42m, which was strengthened by a € 20m equity raise to deliver cash runway into mid-2025.
ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights
ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May 23, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a Q1 2024 business update. “This week’s publication of Up-LIFT pivotal trial resul...
- David Seynnaeve
- PhD
Onward Medical NV - Q1 update brings no surprise
Onward Medical published a Q1 update this morning. Overall, nothing new.All timelines previously communicated are reiterated with the US approval of ARC-EX and the start of the global pivotal study for ARC-IM - Empower-BP - both expected in Q4. Cash runway through mid-25 reiterated as well.Based on the Up-LIFT data and high unmet need for affordable, patient friendly, and efficacious therapies for the SCI community, we consider ONWD to be well-positioned for FDA approval later this year (we curr...
ONWARD® Medical veranstaltet Webcast zu Einzelheiten der Up-LIFT-Studi...
ONWARD® Medical veranstaltet Webcast zu Einzelheiten der Up-LIFT-Studie und der aktuellen Veröffentlichung in Nature Medicine Ergebnisse der Up-LIFT-Zulassungsstudie in Nature Medicine veröffentlicht Besprechung der Ergebnisse der Zulassungsstudie in einem Webcast in dieser Woche mit Führungskräften des Unternehmens, Studienleitern und Teilnehmern EINDHOVEN, Niederlande, May 22, 2024 (GLOBE NEWSWIRE) -- Wie ONWARD Medical N.V. (Euronext: ONWD), das Medizintechnikunternehmen, das innovative Therapien zur Stimulation des Rückenmarks entwickelt, um Bewegung, Funktion und Unabhängigkeit von...
ONWARD® Medical organise une téléconférence pour partager les détails ...
ONWARD® Medical organise une téléconférence pour partager les détails relatifs à son étude clinique Up-LIFT et à sa publication dans la revue Nature Medicine La revue Nature Medicine a publié les résultats de l’essai clinique pivot Up-LIFT ONWARD Medical présentera les résultats de cet essai pivot à l’occasion d’une téléconférence organisée cette semaine avec le concours de sa Direction et des principaux investigateurs et participants à l’étude EINDHOVEN, Pays-Bas, 22 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de théra...
- Jacob Mekhael
- Thomas Vranken
Onward Medical Pivotal Up-LIFT data published in Nature
Onward published detailed results of its pivotal Up-LIFT trial for ARCEX in the renowned magazine Nature. The data elaborates on the previously announced 72% response rate, revealing meaningful improvements across strength, function, sensory and quality of life, and demonstrates the safety of the therapy. Importantly, responses did not plateau toward the end of the observation period, and could therefore still increase in longer-term follow-up. With anticipated FDA approval toward YE24, we reite...
Nature Medicine hebt signifikante Verbesserung der Hand- und Armfunkti...
Nature Medicine hebt signifikante Verbesserung der Hand- und Armfunktion nach einer Rückenmarksverletzung durch die ONWARD® ARC-EX® Therapie hervor ARC Therapy™ hat sich in einer globalen Zulassungsstudie* als sicher und wirksam erwiesen 90 % der Teilnehmer verbesserten entweder die Kraft oder die Funktion der oberen Gliedmaßen* Verbesserung bei Teilnehmern bis zu 34 Jahre nach der Verletzung nachgewiesen* 87 % der Teilnehmer berichteten auch über eine Verbesserung der allgemeinen Lebensqualität* EINDHOVEN, Niederlande, May 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: O...
Nature Medicine se réjouit de partager l’amélioration significative de...
Nature Medicine se réjouit de partager l’amélioration significative de la fonction de la main et du bras après une lésion de la moelle épinière grâce à la thérapie ONWARD® ARC-EX® Therapy La thérapie ARC Therapy™ s’est révélée sûre et efficace dans le cadre d’une étude pivot mondiale* Quatre-vingt-dix pour cent des participants ont amélioré la force ou la fonction de leurs membres supérieurs* Amélioration démontrée chez les participants jusqu’à 34 ans après la blessure* Quatre-vingt-sept pour cent des participants ont également fait état d’une amélioration de leur qualité de vie globale*...
ONWARD® Medical to Host Webcast to Share Details from its Up-LIFT Tria...
ONWARD® Medical to Host Webcast to Share Details from its Up-LIFT Trial and Yesterday’s Nature Medicine Publication Nature Medicine published Up-LIFT pivotal trial results Company will discuss pivotal trial results during webcast this week with company leaders and study principal investigators and participants EINDHOVEN, the Netherlands, May 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today an...
- David Seynnaeve
- PhD
Onward Medical NV - Up-LIFT data published in Nature Medicine
ONWD announced that the detailed data of Up-LIFT, the pivotal study with ARC-EX for arm & hand mobility in spinal cord injury (SCI) patients, has been published in Nature Medicine, one of the world's most eminent scientific journals. Remember that both primary efficacy and safety endpoints were met with results indicating 1/ significant improvements in hand & arm strength and functional performance, 2/ improved recovery of sensory function, & 3/ a decrease in frequency and severity of muscl...
Nature Medicine Highlights Significant Improvement in Hand and Arm Fun...
Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy ARC Therapy™ shown to be safe and effective in global pivotal trial* 90% of participants improved either strength or function of upper limbs* Improvement demonstrated in participants up to 34 years post-injury* 87% of participants also reported improvement in overall quality of life* EINDHOVEN, the Netherlands, May 20, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimul...
ONWARD® Medical plant Webcast zur Vorstellung des Geschäftsverlaufs im...
ONWARD® Medical plant Webcast zur Vorstellung des Geschäftsverlaufs im 1. Quartal 2024 EINDHOVEN, Niederlande, May 16, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), das Medizintechnologieunternehmen, das innovative Rückenmarkstimulationstherapien entwickelt, um die Bewegung, Funktion und Unabhängigkeit von Menschen mit Rückenmarksverletzungen (Spinal Cord Injury, SCI) wiederherzustellen, gibt heute die Veranstaltung eines Webcasts zu den Geschäftsergebnissen des ersten Quartals 2024 bekannt. Der Webcast wird am 23. Mai 2024 um 14:30 Uhr MEZ/08:30 Uhr ET stattfinden. Gast...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.